Drugs / Novolin 30R Penfil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05306028 | Aug 2022 → Mar 2025 overdue | diabetes mellitus, malignant pancreatic neoplasm | Fudan University | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novolin 30R Penfil | “Novolin 30R Penfil 12 U before breakfast, 8 U” NCT05306028 ↗ |